Lynx to Perform Study for Genome Institute of Singapore
By Biotechdaily staff writers
Posted on 18 Mar 2003
An agreement to conduct a comparative transcriptome study for the Genome Institute of Singapore at the National University of Singapore (GIS) has been announced by Lynx Therapeutics, Inc. (Hayward, CA, USA).Posted on 18 Mar 2003
Lynx will use its massively parallel signature sequencing (MPSS) technology to generate comprehensive gene expression profiles from matched samples of human, mouse, and fish tissues. GIS will pay Lynx for the genomics discovery services performed on the GIS samples. Following a successful outcome, GIS and Lynx expect to have a broader relationship and to couple the biologic expertise of GIS with the transcriptome profiling ability of Lynx' MPSS.
"We believe that this agreement between Lynx and GIS is an example of combining a powerful technology with broad biologic interests,” said Dr. Edison Liu, executive director of GIS. "By integrating MPSS with other technologies established in GIS, we intend to characterize transcriptomes in depth, annotate genomes with greater precision, and discover genes with practical implementation.”
Related Links:
Genome Institute of Singapore
Lynx
Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
